Xiaoxv Dong1,2, Yawen Zeng1, Zhiqin Zhang1, Jing Fu3, Longtai You1, Yuanyuan He2, Yang Hao2, Zili Gu2, Zhenfeng Yu2, Changhai Qu1, Xingbin Yin1, Jian Ni1,4, Luis J Cruz2. 1. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. 2. Department of Radiology, Division of Translational Nanobiomaterials and Imaging, Leiden University Medical Center, Leiden, The Netherlands. 3. Beijing Institute of Traditional Chinese Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China. 4. Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Abstract
OBJECTIVES: Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally. It is also an active ingredient in some species of the genus Hypericum. Emerging evidence suggests that hypericin has attracted great attention as a potential anticancer drug and exhibits remarkable antiproliferative effect upon irradiation on various tumour cells. This paper aims to summarise the anticancer effect and molecular mechanisms modulated by hypericin-medicated photodynamic therapy and its potential role in the cancer treatment. KEY FINDINGS: Hypericin-medicated photodynamic therapy could inhibit the proliferation of various tumour cells including bladder, colon, breast, cervical, glioma, leukaemia, hepatic, melanoma, lymphoma and lung cancers. The effect is primarily mediated by p38 mitogen-activated protein kinase (MAPK), JNK, PI3K, CCAAT-enhancer-binding protein homologous protein (CHOP)/TRIB3/Akt/mTOR, TRAIL/TRAIL-receptor, c-Met and Ephrin-Eph, the mitochondria and extrinsic signalling pathways. Furthermore, hypericin-medicated photodynamic therapy in conjunction with chemotherapeutic agents or targeted therapies is more effective in inhibiting the growth of tumour cells. SUMMARY: During the past few decades, the anticancer properties of photoactivated hypericin have been extensively investigated. Hypericin-medicated photodynamic therapy can modulate a variety of proteins and genes and exhibit a great potential to be used as a therapeutic agent for various types of cancer.
OBJECTIVES:Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally. It is also an active ingredient in some species of the genus Hypericum. Emerging evidence suggests that hypericin has attracted great attention as a potential anticancer drug and exhibits remarkable antiproliferative effect upon irradiation on various tumour cells. This paper aims to summarise the anticancer effect and molecular mechanisms modulated by hypericin-medicated photodynamic therapy and its potential role in the cancer treatment. KEY FINDINGS:Hypericin-medicated photodynamic therapy could inhibit the proliferation of various tumour cells including bladder, colon, breast, cervical, glioma, leukaemia, hepatic, melanoma, lymphoma and lung cancers. The effect is primarily mediated by p38 mitogen-activated protein kinase (MAPK), JNK, PI3K, CCAAT-enhancer-binding protein homologous protein (CHOP)/TRIB3/Akt/mTOR, TRAIL/TRAIL-receptor, c-Met and Ephrin-Eph, the mitochondria and extrinsic signalling pathways. Furthermore, hypericin-medicated photodynamic therapy in conjunction with chemotherapeutic agents or targeted therapies is more effective in inhibiting the growth of tumour cells. SUMMARY: During the past few decades, the anticancer properties of photoactivated hypericin have been extensively investigated. Hypericin-medicated photodynamic therapy can modulate a variety of proteins and genes and exhibit a great potential to be used as a therapeutic agent for various types of cancer.
Authors: Miriam C Bassler; Tim Rammler; Frank Wackenhut; Sven Zur Oven-Krockhaus; Ivona Secic; Rainer Ritz; Alfred J Meixner; Marc Brecht Journal: Anal Bioanal Chem Date: 2022-05-10 Impact factor: 4.478
Authors: Terézia Zajičková; Eva Horváthová; Stanislav Kyzek; Eva Šályová; Eva Túryová; Andrea Ševčovičová; Eliška Gálová Journal: Int J Mol Sci Date: 2022-05-10 Impact factor: 6.208
Authors: Aline da Rocha Matos; Braulia Costa Caetano; João Luiz de Almeida Filho; Jéssica Santa Cruz de Carvalho Martins; Michele Gabrielle Pacheco de Oliveira; Thiago das Chagas Sousa; Marco Aurélio Pereira Horta; Marilda Mendonça Siqueira; Jorge Hernandez Fernandez Journal: Front Microbiol Date: 2022-02-10 Impact factor: 5.640
Authors: Yang Hao; Chih Kit Chung; Zhenfeng Yu; Ruben V Huis In 't Veld; Ferry A Ossendorp; Peter Ten Dijke; Luis J Cruz Journal: Pharmaceutics Date: 2022-01-04 Impact factor: 6.321